PE20211860A1 - Proteinas de union multiespecificas que se unen a bcma, nkg2d y cd16 y metodos de uso - Google Patents
Proteinas de union multiespecificas que se unen a bcma, nkg2d y cd16 y metodos de usoInfo
- Publication number
- PE20211860A1 PE20211860A1 PE2021000169A PE2021000169A PE20211860A1 PE 20211860 A1 PE20211860 A1 PE 20211860A1 PE 2021000169 A PE2021000169 A PE 2021000169A PE 2021000169 A PE2021000169 A PE 2021000169A PE 20211860 A1 PE20211860 A1 PE 20211860A1
- Authority
- PE
- Peru
- Prior art keywords
- binding site
- bcma
- seq
- chain variable
- domain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invencion se refiere a proteinas de union multiespecificas que comprenden un primer sitio de union a NKG2D, un segundo sitio de union al antigeno de maduracion de linfocitos B (BCMA) y un dominio Fc o parte de este para unirse a CD16 o un tercer sitio de union a CD16. Las proteinas de union de la invencion comprenden un primer sitio de union a NKG2D caracterizado por un dominio variable de cadena pesada que se selecciona de las SEQ ID NO: 94, 169, 171, 173, 175, 177 y 179; y un dominio variable de cadena ligera de SEQ ID NO: 98; un segundo sitio de union a BCMA caracterizado por un dominio variable de cadena pesada que se selecciona de las SEQ ID NO: 148, 114, entre otras; y un dominio variable de cadena ligera que se selecciona de las SEQ ID NO: 152, 119, entre otras; adicionalmente comprende un dominio Fc el cual es un dominio de Fc de IgG1 humana que comprende las sustituciones Q347R, D399V, F405T, K360E y/o K409W, entre otras. La invencion tambien se refiere a una formulacion, una celula y un metodo para tratar el cancer tal como: mieloma multiple, leucemia linfoblastica aguda, leucemia linfocitica cronica, linfomas de linfocitos B y leucemia mieloide aguda. Las proteinas de union multiespecificas proporcionadas en la presente exhiben alta potencia y lisis maxima de celulas cancerigenas objetivo en comparacion con anticuerpos monoclonales anti-BCMA.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862716207P | 2018-08-08 | 2018-08-08 | |
PCT/US2019/045632 WO2020033630A1 (en) | 2018-08-08 | 2019-08-08 | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20211860A1 true PE20211860A1 (es) | 2021-09-21 |
Family
ID=69413838
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2021000169A PE20211860A1 (es) | 2018-08-08 | 2019-08-08 | Proteinas de union multiespecificas que se unen a bcma, nkg2d y cd16 y metodos de uso |
Country Status (19)
Country | Link |
---|---|
US (2) | US20210317223A1 (es) |
EP (1) | EP3833392A4 (es) |
JP (1) | JP2021533169A (es) |
KR (1) | KR20210043602A (es) |
CN (1) | CN112823022A (es) |
AR (1) | AR114544A1 (es) |
AU (1) | AU2019318083A1 (es) |
BR (1) | BR112021002072A2 (es) |
CA (1) | CA3108427A1 (es) |
CL (1) | CL2021000316A1 (es) |
CO (1) | CO2021001410A2 (es) |
EA (1) | EA202190468A1 (es) |
IL (1) | IL280512A (es) |
MA (1) | MA53293A (es) |
MX (1) | MX2021001524A (es) |
PE (1) | PE20211860A1 (es) |
SG (1) | SG11202100883SA (es) |
TW (1) | TW202019479A (es) |
WO (1) | WO2020033630A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3237846A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the nkg2d receptor |
JP2023540618A (ja) * | 2020-09-11 | 2023-09-25 | ブリストル-マイヤーズ スクイブ カンパニー | 癌の併用療法 |
WO2023011431A1 (zh) * | 2021-08-03 | 2023-02-09 | 江苏先声药业有限公司 | 一种cd16抗体及其应用 |
WO2023107956A1 (en) * | 2021-12-08 | 2023-06-15 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and 5t4 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014100490A1 (en) * | 2012-12-19 | 2014-06-26 | Adimab, Llc | Multivalent antibody analogs, and methods of their preparation and use |
PT3331910T (pt) * | 2015-08-03 | 2020-03-24 | Engmab Sarl | Anticorpos monoclonais contra o antigénio de maturação de células b (bcma) humano |
CA3016563A1 (en) * | 2016-03-21 | 2017-09-28 | Elstar Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
CN110177803A (zh) * | 2016-11-22 | 2019-08-27 | T细胞受体治疗公司 | 用于使用融合蛋白进行tcr重新编程的组合物和方法 |
MA47465A (fr) * | 2017-02-10 | 2019-12-18 | Dragonfly Therapeutics Inc | Protéines fixant le bcma, le nkg2d et le cd16 |
-
2019
- 2019-08-08 TW TW108128372A patent/TW202019479A/zh unknown
- 2019-08-08 SG SG11202100883SA patent/SG11202100883SA/en unknown
- 2019-08-08 MX MX2021001524A patent/MX2021001524A/es unknown
- 2019-08-08 KR KR1020217006411A patent/KR20210043602A/ko active Search and Examination
- 2019-08-08 EA EA202190468A patent/EA202190468A1/ru unknown
- 2019-08-08 BR BR112021002072-1A patent/BR112021002072A2/pt unknown
- 2019-08-08 AU AU2019318083A patent/AU2019318083A1/en active Pending
- 2019-08-08 AR ARP190102253A patent/AR114544A1/es unknown
- 2019-08-08 CN CN201980066329.9A patent/CN112823022A/zh active Pending
- 2019-08-08 CA CA3108427A patent/CA3108427A1/en active Pending
- 2019-08-08 WO PCT/US2019/045632 patent/WO2020033630A1/en active Application Filing
- 2019-08-08 PE PE2021000169A patent/PE20211860A1/es unknown
- 2019-08-08 EP EP19848231.7A patent/EP3833392A4/en active Pending
- 2019-08-08 MA MA053293A patent/MA53293A/fr unknown
- 2019-08-08 JP JP2021506559A patent/JP2021533169A/ja active Pending
- 2019-08-08 US US17/266,349 patent/US20210317223A1/en active Pending
-
2021
- 2021-01-29 IL IL280512A patent/IL280512A/en unknown
- 2021-02-05 CL CL2021000316A patent/CL2021000316A1/es unknown
- 2021-02-08 CO CONC2021/0001410A patent/CO2021001410A2/es unknown
- 2021-12-06 US US17/543,628 patent/US20220089760A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3833392A1 (en) | 2021-06-16 |
AR114544A1 (es) | 2020-09-16 |
CN112823022A (zh) | 2021-05-18 |
EA202190468A1 (ru) | 2021-07-06 |
TW202019479A (zh) | 2020-06-01 |
CA3108427A1 (en) | 2020-02-13 |
SG11202100883SA (en) | 2021-02-25 |
US20210317223A1 (en) | 2021-10-14 |
US20220089760A1 (en) | 2022-03-24 |
MA53293A (fr) | 2021-11-17 |
CL2021000316A1 (es) | 2021-07-30 |
AU2019318083A1 (en) | 2021-02-25 |
MX2021001524A (es) | 2021-04-19 |
IL280512A (en) | 2021-03-25 |
BR112021002072A2 (pt) | 2021-06-01 |
EP3833392A4 (en) | 2022-05-18 |
WO2020033630A1 (en) | 2020-02-13 |
KR20210043602A (ko) | 2021-04-21 |
CO2021001410A2 (es) | 2021-05-10 |
JP2021533169A (ja) | 2021-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20211860A1 (es) | Proteinas de union multiespecificas que se unen a bcma, nkg2d y cd16 y metodos de uso | |
AR106184A1 (es) | Proteínas de unión a pd-1 y sus métodos de uso | |
PE20190120A1 (es) | Moleculas de union a bcma y metodos de uso de las mismas | |
AR110017A1 (es) | Anticuerpos de pd-1 y usos de estos | |
CR20200567A (es) | Anticuerpos anti-cd33, anticuerpos biespecíficos anti-cd33/anti-cd3 y usos de estos | |
PE20190356A1 (es) | Receptores quimericos y metodos de uso de los mismos | |
PE20181921A1 (es) | NUEVOS ANTICUERPOS ANTI-SIRPa Y SUS APLICACIONES TERAPEUTICAS | |
PE20181451A1 (es) | Anticuerpos neutralizadores del virus de inmunodeficiencia humana | |
PE20180046A1 (es) | Anticuerpos terapeuticos y sus usos | |
AR106570A1 (es) | Anticuerpos anti-psma, moléculas de unión al antígeno biespecíficas que se unen a psma y cd3, y usos de estos | |
BR112017014551A2 (pt) | ?anticorpo, construção de ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos para tratamento de uma doença, para produção de um anticorpo biespecífico e para detecção da possível ocorrência de reticulação entre células com expressão de cd3 e cd20 em uma amostra derivada de um paciente, uso de um anticorpo biespecífico, e, kit? | |
PE20240218A1 (es) | Anticuerpos madurados por afinidad y humanizados para fcrh5 | |
AR106199A1 (es) | Moléculas de unión a antígeno biespecíficas activadoras de células t | |
CO2019012143A2 (es) | Formulaciones estables de anticuerpos anti-ctla4 solos y en combinación con anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso | |
PE20220278A1 (es) | Dominios variables de anticuerpos que se dirigen al receptor nkg2d | |
EA202092907A1 (ru) | Мультиспецифические связывающие белки и их усовершенствования | |
PE20191759A1 (es) | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos | |
RU2018112649A (ru) | Композиция для лечения рака, объединяющая анти-cd26 антитело и другое противораковое средство | |
EA202191785A1 (ru) | Антитела к ctla4 и способы их применения | |
PE20180802A1 (es) | Anticuerpos anti-cd154 y metodos de uso de estos | |
CO2022006909A2 (es) | Anticuerpos contra el virus de la fiebre amarilla y métodos de su generación y uso | |
AR104906A1 (es) | Anticuerpos dirigidos a la proteína morfogenética ósea 9 (bmp9) y métodos a partir de estos | |
AR083971A1 (es) | Anticuerpos antiproliferacion humanizados homogeneos | |
EA202092122A1 (ru) | Антитела против tip-1 и их применения | |
MX2023006817A (es) | Composiciones y metodos relacionados con anticuerpos activados por tumores dirigidos a psma y antigenos de celulas efectoras. |